Press Releases Events & Presentations Event Details ESCMID – Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025 Apr 15, 2025 Supporting Materials ABI-5366 – The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants 554.8 KB ABI-5366 – Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes 582.6 KB HSV – Estimating Genital Herpes Prevalence and Treatment Patterns Among U.S. Healthcare-Engaged Individuals: Insights from Claims Data 272.6 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
ESCMID – Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025 Apr 15, 2025 Supporting Materials ABI-5366 – The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants 554.8 KB ABI-5366 – Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes 582.6 KB HSV – Estimating Genital Herpes Prevalence and Treatment Patterns Among U.S. Healthcare-Engaged Individuals: Insights from Claims Data 272.6 KB
ABI-5366 – The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants 554.8 KB
ABI-5366 – Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes 582.6 KB
HSV – Estimating Genital Herpes Prevalence and Treatment Patterns Among U.S. Healthcare-Engaged Individuals: Insights from Claims Data 272.6 KB
